“Valuing Statistical Absences? Why Benefit-Cost Analysis Cannot Avoid Population Ethics”
Andrew Stawasz- Administrative Law
Ecological Economics
2025
University of Michigan Journal of Law Reform
2024
“Health Technology Assessment for Vaccines Against Rate, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination’s Full Social and Economic Benefits”
Andrew Stawasz
Frontiers in Public Health
2020
“Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? The Perils of Undervaluation”
Andrew Stawasz
The Pediatric Infectious Disease Journal
2020
“Indirect Costs of Adult Pneumococcal Disease and the Productivity-Based Rate of Return to the 13-Valent Pneumococcal Conjugate Vaccine for Adults in Turkey”
Andrew Stawasz
Human Vaccines and Immunotherapueutics
2020
“Indirect Costs of Adult Penumococcal Disease and Productivity-Based Rate of Return to PCV13 Vaccination for Older Adults and Elderly Diabetics in Denmark”
Andrew Stawasz
The Journal of the Economics of Aging
2019
“Linking Health and Education: Commentary on “Childhood Infections and Subsequent School Achievment Among 598,553 Danish Children””
Andrew Stawasz
The Pediatric Infectious Disease Journal
2018
“The Full Benefits of Adult Pneumococcal Vaccination: A Systematic Review”
Andrew Stawasz
Plos ONE
2017
“Environmental-Economic Policy Tools for the 21st Century: Ecosystem Services, Environmental Services, and Changes in Natural Capital”
Andrew Stawasz
Research Handbook for Ecosystem Services